Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HK1 | P19367 | 3/20 | 0.41 |
| ▸ | HK2 | P52789 | 3/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18391246 | 1.00 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL26229737 | 1.00 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL13240509 | 1.00 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL4314010 | 1.00 | MAPK1 (0.49) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL29764270 | 0.88 | MAPK1 (0.47) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL12280200 | 0.86 | MAPK1 (0.46) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL8038552 | 0.86 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL22394176 | 0.86 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL8038560 | 0.86 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL29764253 | 0.86 | MAPK1 (0.48) | MAPK1AMDHD2ALDH1A1THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | MAPK1 2043/4885AMDHD2 208/4885ALDH1A1 3655/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | MAPK1 3302/4885AMDHD2 2737/4885ALDH1A1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.